Multi-year Innovation Program Designed to
Maximize Value and Outcomes for XT Automated Dispensing System
Omnicell, Inc. (Nasdaq:OMCL) (“Omnicell” or the “Company”), a
leader in transforming the pharmacy care delivery model, today
announced XT Amplify, a multi-year innovation program that is
intended to maximize value for hospitals, health systems, and
post-acute care facilities that have invested in Omnicell’s XT
Automated Dispensing System while also seeking to drive enhanced
clinical and operational outcomes at the points of care and within
pharmacies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240416872419/en/
XT Amplify - Innovative solutions
designed to enhance pharmacy and nursing efficiency, reduce
medication errors and waste, and ultimately maximize the value of
XT Automated Dispensing System (Photo: Business Wire)
“We recognize that some of our customers are navigating
difficult operational and economic environments. We believe
Omnicell is nicely positioned to address these current challenges
while adapting for the future,” said Randall Lipps, chairman,
president, chief executive officer, and founder of Omnicell. “We
are confident the XT Amplify program will deliver continuous
innovation that addresses these evolving and complex needs, while
helping customers to maximize outcomes and the value of Omnicell
automated dispensing systems currently in use around the
globe.”
The solutions within the multi-year XT Amplify program are
intended to enhance nursing efficiency, reduce medication errors
and waste, and, ultimately, help health systems achieve the
aspirational outcomes outlined in the industry-defined vision of
the Autonomous Pharmacy. The first set of solutions that will be
available in North America include:
XTExtend: This comprehensive console
swap is intended to provide a high level of security while
enhancing the user experience. Designed to be backward compatible,
the console aims to strengthen interoperability within the
healthcare facility, while maximizing value of current
technology.
MedChill: Intended to improve the
safety and security of individual, temperature-controlled
medications, this secure device for compatible refrigeration
supports item-level inventory visibility that is designed to
maximize expiration dates to reduce waste and stockouts at the
points of care and within pharmacies.
SupplyXpert: This inventory management
software is designed to manage medical supplies housed within the
XT Supply cabinet and open-shelf locations, providing insights into
stockout events, stock value, key performance indicators, and
optimization recommendations. This should extend the benefits of
existing equipment while helping customers manage the increasing
costs of medical supplies.
ServerScale: The on-premises
OmniCenter virtual server solution is now available in a
subscription format, that is intended to allow customers to stay
current with the latest operating systems in an effort to ensure
infrastructure readiness today, while providing a foundation for
the evolving and expanding health system.
CarePlus: Omnicell’s market-leading
automation solutions are now supported by expert services that are
designed to improve solution adoption and provide data-driven
performance optimization information that is expected to enhance
nursing and pharmacy efficiency.
XT Amplify is intended to enable all healthcare facilities,
regardless of where they are in their adoption and utilization of
Omnicell’s XT Automated Dispensing System, to solve important
challenges today and into the future.
“We recognize the value of technology-driven medication
management. But installing a new infrastructure and the change
management that comes with that can be very challenging,” said
Jennifer Hillman, PharmD, executive director of Pharmacy at San
Antonio-based University Health. “XT Amplify provides us a path to
implement innovative new solutions while maximizing the value of
our existing technology investments.”
XT Amplify is designed to support healthcare facilities as they
advance toward the industry-defined vision of the Autonomous
Pharmacy that seeks to replace manual, error-prone activities with
automated processes that are intended to be safer and more
efficient. To learn more, visit omnicell.com/XTAmplify.
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy
care through outcomes-centric innovation designed to optimize
clinical and business outcomes across all settings of care. Through
a comprehensive portfolio of robotics, smart devices, intelligent
software, and expert services, Omnicell solutions are helping
healthcare facilities worldwide to reduce costs, improve labor
efficiency, establish new revenue streams, enhance supply chain
control, support compliance, and move closer to the industry vision
of the Autonomous Pharmacy. To learn more, visit omnicell.com.
From time to time, Omnicell may use the Company’s investor
relations website and other online social media channels, including
its LinkedIn page www.linkedin.com/company/omnicell, and Facebook
page www.facebook.com/omnicellinc, to disclose material non-public
information and comply with its disclosure obligations under
Regulation Fair Disclosure (“Reg FD”).
OMNICELL and the Omnicell logo are registered trademarks of
Omnicell, Inc. or one of its subsidiaries.
Forward-Looking Statements
To the extent any statements contained in this press release
deal with information that is not historical, these statements are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Without limiting the
foregoing, statements including the words “expect,” “intend,”
“may,” “will,” “should,” “would,” “could,” “plan,” “potential,”
“anticipate,” “believe,” “forecast,” “guidance,” “outlook,”
“goals,” “target,” “estimate,” “seek,” “predict,” “project,” and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are subject to the
occurrence of many events outside Omnicell’s control. Such
statements include, but are not limited to, Omnicell’s planned new
products and services or developing enhancements to existing
products and services, including XTExtend, MedChill, SupplyXpert),
ServerScale, and CarePlus, and the related objectives and expected
benefits (and any implied financial impact), and statements about
Omnicell’s strategy, plans, objectives, promise and purpose, goals,
opportunities, and market or Company outlook. Actual results and
other events may differ significantly from those contemplated by
forward-looking statements due to numerous factors that involve
substantial known and unknown risks and uncertainties. These risks
and uncertainties include, among other things, (i) unfavorable
general economic and market conditions, including the impact and
duration of inflationary pressures, (ii) Omnicell’s ability to take
advantage of growth opportunities and develop and commercialize new
solutions and enhance existing solutions, (iii) reduction in demand
in the capital equipment market or reduction in the demand for or
adoption of our solutions, systems, or services, (iv) delays in
installations of our medication management solutions or our more
complex medication packaging systems, (v) risks related to
Omnicell’s investments in new business strategies or initiatives,
including its transition to selling more products and services on a
subscription basis (vi) risks related to failing to maintain
expected service levels when providing our Advanced Services or
retaining our Advanced Services customers, (vii) Omnicell’s ability
to meet the demands of, or maintain relationships with, its
institutional, retail, and specialty pharmacy customers, (viii)
continued and increased competition from current and future
competitors in the medication management automation solutions
market and the medication adherence solutions market, (ix) risks
presented by government regulations, legislative changes, fraud and
anti-kickback statues, products liability claims, the outcome of
legal proceedings, and other legal obligations related to
healthcare, privacy, data protection, and information security,
including any potential governmental investigations and enforcement
actions, litigation, fines and penalties, exposure to
indemnification obligations or other liabilities, and adverse
publicity as a result of the previously disclosed ransomware
incident, (x) any disruption in Omnicell’s information technology
systems and breaches of data security or cyber-attacks on its
systems or solutions, including the previously disclosed ransomware
incident and any potential adverse legal, reputational, and
financial effects that may result from it and/or additional
cybersecurity incidents, as well as the effectiveness of business
continuity plans during any future cybersecurity incidents,
countries, (xi) Omnicell’s ability to recruit and retain skilled
and motivated personnel, (xii) Omnicell’s ability to protect its
intellectual property, (xiii) risks related to the availability and
sources of raw materials and components or price fluctuations,
shortages, or interruptions of supply, (xiv) Omnicell’s dependence
on a limited number of suppliers for certain components, equipment,
and raw materials, as well as technologies provided by third-party
vendors, and (xv) other risks and uncertainties further described
in the “Risk Factors” section of Omnicell’s most recent Annual
Report on Form 10-K, as well as in Omnicell’s other reports filed
with or furnished to the United States Securities and Exchange
Commission (“SEC”), available at . Forward-looking statements
should be considered in light of these risks and uncertainties.
Investors and others are cautioned not to place undue reliance on
forward-looking statements. All forward-looking statements
contained in this press release speak only as of the date of this
press release. Omnicell assumes no obligation to update any such
statements publicly, or to update the reasons actual results could
differ materially from those expressed or implied in any
forward-looking statements, whether as a result of changed
circumstances, new information, future events, or otherwise, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240416872419/en/
Betsy Martinelli Director, Corporate Marketing
betsy.martinelli@omnicell.com
Omnicell (NASDAQ:OMCL)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Omnicell (NASDAQ:OMCL)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024